New Key Statistics Module, Z-Score and F-Score
AMEX:CANF Key Ratios
| Market Cap $ M | 7.39 |
| Enterprise Value $ M | -1.08 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 0.36 |
| Price/Book | 0.80 |
| Price/Sales | 6.65 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -3.78 |
| Beneish M-Score | -3.95 |
| 10-y EBITDA Growth Rate % | 42.30 |
| 5-y EBITDA Growth Rate % | 46.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.11 |
| EV-to-EBITDA | 0.11 |
| PEG | -- |
| Shares Outstanding M | 2.14 |
| Net Margin (%) | -2,427.82 |
| Operating Margin % | -2,458.03 |
| Pre-tax Margin (%) | -2,427.82 |
| Quick Ratio | 3.46 |
| Current Ratio | 3.46 |
| ROA % (ttm) | -111.87 |
| ROE % (ttm) | -193.82 |
| ROIC % (ttm) | -939.94 |
| Dividend Yield % | -- |
| Altman Z-Score | -27.32 |
CANF Number of Guru Trades
CANF Volume of Guru Trades
Gurus Latest Trades with AMEX:CANF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
AMEX:CANF is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Can Fite Biopharma Ltd Insider Transactions
No Available Data
News about AMEX:CANF
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers